Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

Syntimmune
257 Park Avenue South 15th Floor
New York, NY 10010
Phone: 212-498-0011
http://syntimmune.com/

Founded in 2013, Syntimmune is advancing novel therapies based on its leading position in the biology of the neonatal Fc receptor (FcRn). FcRn is a well-validated target for IgG-mediated autoimmune diseases and represents a central common pathway that enables abnormal IgG responses. Syntimmune's lead candidate, SYNT001, is a biologic progressing through IND-enabling studies that specifically blocks the FcRn-IgG interaction and is being developed for the treatment of IgG-mediated autoimmune diseases. Syntimmune has two additional, earlier-stage therapeutic programs, targeting other unique aspects of FcRn biology. The Syntimmune team has world-class experience in the field of FcRn biology and has successfully pioneered and advanced biologics targeting FcRn, including approved therapies currently on the market.

Key Contact
Name
Laurence Blumberg, M.D.
Title
CEO and Co-Founder
Funding Events

Date
Amount
Type
Investors
Valuation
03/22/16 $10,000,000 Series A Apple Tree Partners
Baxalta Ventures
undisclosed


Featured Reading